Targeting T cells to tumor: exploiting the chimeric antibody receptor.
Adoptive therapy using gene-modified T cells to express chimeric antigen receptors (CARs) is gaining pace in the clinic, particularly in hematological malignancies. Translation into treatment of solid tumors has been slower, not least because of the lack of truly tumor-specific target antigens. Alonso-Camino et al. describe experiments that further develop the concept of using the therapeutic entity (in this case, the CAR T cell) to screen for functional binding of tumor target cells. This article highlights the potential for the approach, but also underlies some of the key hurdles that remain to be overcome in order to produce a functional antibody-based screening approach that is able to identify novel tumor antigens that can be recognized by CAR T cells.